An interventional study of Stellate Ganglion Block Injection with Bupivicaine and Sham procedure control in Ventricular Tachycardia (V-Tach) Storm, sponsored by Population Health Research Institute. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Population Health Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 11th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, reaches primary completion later than 18 of the 18 other live ones, and was the 54th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:
Adagio Medical · Sites in Canada, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Thermedical, Inc. · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
University Hospital, Basel, Switzerland · Sites in Canada, United States, Austria and 13 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 130 across the 39 interventional studies, 1,735 across the 15 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Population Health Research Institute has 2 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
10 of the studies in Tachycardia, Ventricular with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047198Phase 3Ottawa Heart Institute Research CorporationCatheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial | 2026-12-31 |
| NCT06281977Phase 3Ottawa Heart Institute Research CorporationStudy Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm | 2027-05-08 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT03713866John SappPeri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventricular tachycardia (VT) is a serious heart rhythm problem in which the heart beats very fast and in an abnormal way. These abnormal heart rhythms can be life-threatening. When a person has three or more episodes of VT within a 24-hour period, it is called a "VT storm." VT storm can be difficult to treat because some patients do not respond well to standard medications. Some studies suggest that a procedure called a stellate ganglion block (SGB) may help. An SGB involves injecting a local anesthetic near a group of nerves in the neck that help control signals between the brain and the heart. The procedure can be performed at the bedside using ultrasound guidance.
The purpose of this study is to find out whether SGB can delay or prevent the return of dangerous abnormal heart rhythms in patients with VT storm who are receiving care in an intensive care unit.
If a patient joins the study, they will be randomly assigned (by chance, like flipping a coin) to one of two groups. One group will receive a real stellate ganglion block. The other group will receive a sham procedure, in which a blunt needle will touch the skin but no injection will be given. Patients in the sham group who continue to experience VT may later receive the real procedure.
Participants will be followed until they leave the hospital or for 30 days after joining the study, whichever comes first. The study will take place at five hospitals across Ontario.
Stellate ganglion block (SGB) is currently a standard of care option for ventricular tachycardia (VT) storm. However, the evidence to support SBG is derived from non-randomized studies, thus there is a need to test this clinical procedure in an RCT with a sham procedure control. All aspects of the SGB intervention will occur in accordance with local clinical practice, with the exception of control arm participants receiving a sham injection as described below and in the protocol. The study case report forms will be used to collect information related to the local clinical assessments and procedures, as well as participant clinical status and outcomes, but will not dictate local clinical care.
Study summary:
Patients admitted to hospital with VT storm will be approached by study nurse or physician to gain consent for study participation. Study nurse or physician will use web-based randomization (ROME) to allocate participant to intervention or control arm. All participants who give consent will receive aseptic preparation and draping of the site of intervention, scanning with ultrasonography, and marking the site of needle entry with a plastic needle cap, in accordance with local practices. In both arms, a syringe with 10mL 0.5% bupivacaine will be ordered from local clinical supplies and prepared in accordance with institutional practices. The operator will document the intervention delivered in a dedicated case report form. All patients will undergo continuous ECG/telemetry monitoring and ICD interrogation (if applicable) per standard clinical care, for 72 hours following SGB.
SGB Arm:
SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.
Sham procedure arm:
The sham-procedure will use the identical preparatory and procedural steps as described for the active arm. The procedure area will be screened off from the patient's view, and all equipment used in both active and sham arms will be identical and visible in the room. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. A small dressing will be applied to the site in both groups to further conceal which intervention was performed. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will image the stellate ganglion using ultrasound but will not inject it. The operator will discard the unused bupivacaine to maintain blinding.
The study database will be hosted within PHRI's secure data centre, and eCRFs, including those pertaining to participant status and outcomes, will be completed by local site research assistants from available local medical records. No participant questionnaires or study-specific research tests or assessments are included in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB should typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.
Procedure: Stellate Ganglion Block Injection with Bupivicaine
The sham-procedure will use the identical preparatory and procedure steps as described for the active arm. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will discard the unused bupivacaine to maintain blinding.
Other: Sham procedure control
SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB should typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.
The sham-procedure will use the identical preparatory and procedure steps as described for the active arm. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will discard the unused bupivacaine to maintain blinding.
Time to First Ventricular Tachycardia/Ventricular Fibrillation
The primary outcome is the time to first recurrence of sustained VT/VF during the first 72 hours after randomization, following a 15-minute blanking period post intervention.
Time frame: 72 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.
Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 48 months is above that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Population Health Research Institute →